Zurcher Kantonalbank Zurich Cantonalbank decreased its holdings in shares of Elanco Animal Health Incorporated (NYSE:ELAN – Get Rating) by 20.3% in the 1st quarter, HoldingsChannel.com reports. The firm owned 55,738 shares of the company’s stock after selling 14,184 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Elanco Animal Health were worth $1,454,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also made changes to their positions in the company. Dodge & Cox lifted its stake in Elanco Animal Health by 510.5% during the fourth quarter. Dodge & Cox now owns 22,218,300 shares of the company’s stock valued at $630,555,000 after purchasing an additional 18,579,176 shares during the last quarter. State Street Corp increased its holdings in shares of Elanco Animal Health by 5.0% in the fourth quarter. State Street Corp now owns 12,576,000 shares of the company’s stock valued at $356,907,000 after buying an additional 595,779 shares in the last quarter. Goldman Sachs Group Inc. lifted its position in shares of Elanco Animal Health by 11.8% during the 4th quarter. Goldman Sachs Group Inc. now owns 10,564,063 shares of the company’s stock valued at $299,808,000 after acquiring an additional 1,113,073 shares during the last quarter. Starboard Value LP boosted its stake in shares of Elanco Animal Health by 5.1% during the 4th quarter. Starboard Value LP now owns 7,685,555 shares of the company’s stock worth $218,116,000 after acquiring an additional 373,843 shares in the last quarter. Finally, Geode Capital Management LLC grew its holdings in shares of Elanco Animal Health by 3.5% in the 4th quarter. Geode Capital Management LLC now owns 5,604,908 shares of the company’s stock worth $158,838,000 after acquiring an additional 191,387 shares during the last quarter.
NYSE:ELAN opened at $20.45 on Friday. The business’s fifty day moving average price is $22.32 and its 200 day moving average price is $25.13. The firm has a market capitalization of $9.70 billion, a price-to-earnings ratio of -27.63, a PEG ratio of 1.01 and a beta of 0.81. The company has a current ratio of 2.44, a quick ratio of 1.41 and a debt-to-equity ratio of 0.80. Elanco Animal Health Incorporated has a 1-year low of $19.34 and a 1-year high of $37.49.
Elanco Animal Health (NYSE:ELAN – Get Rating) last released its earnings results on Monday, May 9th. The company reported $0.36 earnings per share for the quarter, beating the consensus estimate of $0.35 by $0.01. The company had revenue of $1.23 billion for the quarter, compared to analysts’ expectations of $1.22 billion. Elanco Animal Health had a positive return on equity of 6.61% and a negative net margin of 7.65%. The business’s revenue for the quarter was down 1.4% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.37 EPS. Equities analysts forecast that Elanco Animal Health Incorporated will post 1.17 earnings per share for the current year.
In related news, Director R David Hoover bought 10,000 shares of the firm’s stock in a transaction on Friday, May 20th. The stock was bought at an average price of $23.33 per share, with a total value of $233,300.00. Following the purchase, the director now directly owns 125,000 shares of the company’s stock, valued at approximately $2,916,250. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 6.40% of the stock is currently owned by corporate insiders.
Several equities research analysts have recently commented on ELAN shares. Stifel Nicolaus reduced their target price on Elanco Animal Health from $30.00 to $22.00 and set a “hold” rating for the company in a report on Friday, June 24th. The Goldman Sachs Group decreased their target price on shares of Elanco Animal Health from $37.00 to $32.00 and set a “buy” rating for the company in a report on Thursday, May 19th. Finally, Morgan Stanley cut their price target on shares of Elanco Animal Health to $37.00 and set an “overweight” rating on the stock in a report on Tuesday, May 17th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $32.20.
Elanco Animal Health Company Profile (Get Rating)
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.
Further Reading
Want to see what other hedge funds are holding ELAN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elanco Animal Health Incorporated (NYSE:ELAN – Get Rating).
Receive News & Ratings for Elanco Animal Health Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Elanco Animal Health and related companies with MarketBeat.com’s FREE daily email newsletter.
Source: defenseworld.net
